Rizwan Romee

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/1953638/publications.pdf

Version: 2024-02-01

		159585	98798
105	4,904	30	67
papers	citations	h-index	g-index

107	107	107	6380
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	TP53 and Decitabine in Acute Myeloid Leukemia and Myelodysplastic Syndromes. New England Journal of Medicine, 2016, 375, 2023-2036.	27.0	663
2	Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. Science Translational Medicine, 2016, 8, 357ra123.	12.4	621
3	Cytokine activation induces human memory-like NK cells. Blood, 2012, 120, 4751-4760.	1.4	492
4	First-in-human phase 1 clinical study of the IL-15 superagonist complex ALT-803 to treat relapse after transplantation. Blood, 2018, 131, 2515-2527.	1.4	307
5	Mobilized Peripheral Blood Stem Cells Versus Unstimulated Bone Marrow As a Graft Source for T-Cellâ€“Replete Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide. Journal of Clinical Oncology, 2017, 35, 3002-3009.	1.6	255
6	CD56bright NK cells exhibit potent antitumor responses following IL-15 priming. Journal of Clinical Investigation, 2017, 127, 4042-4058.	8.2	236
7	Preactivation with IL-12, IL-15, and IL-18 Induces CD25 and a Functional High-Affinity IL-2 Receptor on Human Cytokine-Induced Memory-like Natural Killer Cells. Biology of Blood and Marrow Transplantation, 2014, 20, 463-473.	2.0	215
8	Severe Cytokine-Release Syndrome after T Cellâ€“Replete Peripheral Blood Haploidentical Donor Transplantation Is Associated with Poor Survival and Antiâ€“IL-6 Therapy Is Safe and Well Tolerated. Biology of Blood and Marrow Transplantation, 2016, 22, 1851-1860.	2.0	135
9	The IL-15-Based ALT-803 Complex Enhances FcÎ³RIIIa-Triggered NK Cell Responses and In Vivo Clearance of B Cell Lymphomas. Clinical Cancer Research, 2016, 22, 596-608.	7.0	130
10	Outcomes of Allogeneic Hematopoietic Cell Transplantation inÂPatients with Myelofibrosis with Prior Exposure to Janus Kinase 1/2 Inhibitors. Biology of Blood and Marrow Transplantation, 2016, 22, 432-440.	2.0	127
11	Utilizing Cytokines to Function-Enable Human NK Cells for the Immunotherapy of Cancer. Scientifica, 2014, 2014, 1-18.	1.7	104
12	Protective Effect of Cytomegalovirus Reactivation on Relapse after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients Is Influenced by Conditioning Regimen. Biology of Blood and Marrow Transplantation, 2014, 20, 46-52.	2.0	86
13	Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysis. Blood, 2021, 137, 3291-3305.	1.4	85
14	Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia. Cancer Discovery, 2020, 10, 1854-1871.	9.4	83
15	Epidemiology of infections following haploidentical peripheral blood hematopoietic cell transplantation. Transplant Infectious Disease, 2017, 19, e12629.	1.7	75
16	Standardizing Definitions of Hematopoietic Recovery, Graft Rejection, Graft Failure, Poor Graft Function, and Donor Chimerism in Allogeneic Hematopoietic Cell Transplantation: A Report on Behalf of the American Society for Transplantation and Cellular Therapy. Transplantation and Cellular Therapy, 2021, 27, 642-649.	1.2	65
17	Impaired T- and NK-cell reconstitution after haploidentical HCT with posttransplant cyclophosphamide. Blood Advances, 2021, 5, 352-364.	5.2	58
18	Haploidentical Transplantation with Post-Transplantation Cyclophosphamide for High-Risk Acute Lymphoblastic Leukemia. Biology of Blood and Marrow Transplantation, 2017, 23, 318-324.	2.0	54

#	Article	IF	Citations
19	Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT. Haematologica, 2020, 105, 47-58.	3.5	51
20	Comparison of Outcomes after Peripheral Blood Haploidentical versus Matched Unrelated Donor Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia: A Retrospective Single-Center Review. Biology of Blood and Marrow Transplantation, 2016, 22, 1696-1701.	2.0	50
21	Hematopoietic cell transplantation donor-derived memory-like NK cells functionally persist after transfer into patients with leukemia. Science Translational Medicine, 2022, 14, eabm1375.	12.4	49
22	Expansion, persistence, and efficacy of donor memory-like NK cells infused for posttransplant relapse. Journal of Clinical Investigation, 2022, 132, .	8.2	48
23	CAR-T cells targeting a nucleophosmin neoepitope exhibit potent specific activity in mouse models of acute myeloid leukaemia. Nature Biomedical Engineering, 2021, 5, 399-413.	22.5	46
24	Improving natural killer cell cancer immunotherapy. Current Opinion in Organ Transplantation, 2015, 20, 671-680.	1.6	44
25	Haploidentical Hematopoietic Cell Transplant with Post-Transplant Cyclophosphamide and Peripheral Blood Stem Cell Grafts in Older Adults with Acute Myeloid Leukemia or Myelodysplastic Syndrome. Biology of Blood and Marrow Transplantation, 2017, 23, 1736-1743.	2.0	44
26	Memory-like NK cells armed with a neoepitope-specific CAR exhibit potent activity against NPM1 mutated acute myeloid leukemia. Proceedings of the National Academy of Sciences of the United States of America, 2022, 119, .	7.1	44
27	T Cellâ€“Replete Peripheral Blood Haploidentical Hematopoietic Cell Transplantation with Post-Transplantation Cyclophosphamide Results in Outcomes Similar to Transplantation from Traditionally Matched Donors in Active Disease Acute Myeloid Leukemia. Biology of Blood and Marrow Transplantation, 2017, 23, 648-653.	2.0	38
28	Myeloablative vs reduced intensity T-cellâ€“replete haploidentical transplantation for hematologic malignancy. Blood Advances, 2019, 3, 2836-2844.	5.2	38
29	Post-transplant high-dose cyclophosphamide after HLA-matched vs haploidentical hematopoietic cell transplantation for AML. Bone Marrow Transplantation, 2016, 51, 1561-1564.	2.4	34
30	Pseudozyma and other nonâ€Candida opportunistic yeast bloodstream infections in a large stem cell transplant center. Transplant Infectious Disease, 2017, 19, e12664.	1.7	31
31	Key Aspects of the Immunobiology of Haploidentical Hematopoietic Cell Transplantation. Frontiers in Immunology, 2020, 11, 191.	4.8	30
32	Cytokine-induced memory-like natural killer cells for cancer immunotherapy. Stem Cell Research and Therapy, 2021, 12, 592.	5.5	28
33	Cardiomyopathy in patients after posttransplant cyclophosphamideâ€“based hematopoietic cell transplantation. Cancer, 2017, 123, 1800-1809.	4.1	27
34	HLA-haploidentical vs matched-sibling hematopoietic cell transplantation: a systematic review and meta-analysis. Blood Advances, 2019, 3, 2581-2585.	5.2	27
35	Halfway there: the past, present and future of haploidentical transplantation. Bone Marrow Transplantation, 2017, 52, 1-6.	2.4	26
36	Cytokine release syndrome after haploidentical hematopoietic cell transplantation: an international multicenter analysis. Bone Marrow Transplantation, 2021, 56, 2763-2770.	2.4	25

#	Article	IF	Citations
37	Haploidentical transplantation using G-CSF-mobilized T-cell replete PBSCs and post-transplantation CY after non-myeloablative conditioning is safe and is associated with favorable outcomes. Bone Marrow Transplantation, 2014, 49, 1124-1126.	2.4	24
38	Alternative donor transplantation for acute myeloid leukemia in patients aged â‰¥50 years: young HLA-matched unrelated or haploidentical donor?. Haematologica, 2020, 105, 407-413.	3.5	23
39	COVID-19 and hematopoietic stem cell transplantation and immune effector cell therapy: a US cancer center experience. Blood Advances, 2021, 5, 861-871.	5.2	23
40	Allogeneic hematopoietic cell transplantation after prior targeted therapy for high-risk chronic lymphocytic leukemia. Blood Advances, 2020, 4, 4113-4123.	5.2	22
41	Activation of Tumor-Cell STING Primes NK-Cell Therapy. Cancer Immunology Research, 2022, 10, 947-961.	3.4	22
42	Donor-lymphocyte infusion following haploidentical hematopoietic cell transplantation with peripheral blood stem cell grafts and PTCy. Bone Marrow Transplantation, 2017, 52, 1623-1628.	2.4	21
43	Propensity Score Analysis of Conditioning Intensity in Peripheral Blood Haploidentical Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2018, 24, 2047-2055.	2.0	18
44	Post-Transplantation Cyclophosphamide Is Associated with an Increase in Non-Cytomegalovirus Herpesvirus Infections in Patients with Acute Leukemia and Myelodysplastic Syndrome. Transplantation and Cellular Therapy, 2022, 28, 48.e1-48.e10.	1.2	18
45	Innovative Strategies to Improve the Clinical Application of NK Cell-Based Immunotherapy. Frontiers in Immunology, 2022, 13, 859177.	4.8	18
46	HLA epitope mismatch in haploidentical transplantation is associated with decreased relapse and delayed engraftment. Blood Advances, 2018, 2, 3590-3601.	5.2	16
47	BK virusâ€“specific T-cell immune reconstitution after allogeneic hematopoietic cell transplantation. Blood Advances, 2020, 4, 1881-1893.	5.2	16
48	Ibrutinib in Steroid-Refractory Chronic Graft-versus-Host Disease, a Single-Center Experience. Transplantation and Cellular Therapy, 2021, 27, 990.e1-990.e7.	1.2	16
49	Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease. Bone Marrow Transplantation, 2021, 56, 1006-1012.	2.4	15
50	Allogeneic hematopoietic cell transplantation outcomes in patients with Richterâ€™s transformation. Haematologica, 2021, 106, 3219-3222.	3.5	15
51	Incidence, Predictors, and Outcomes of Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2020, 26, 529-539.	2.0	14
52	Hematologic Recovery after Pretransplant Chemotherapy Does Not Influence Survival after Allogeneic Hematopoietic Cell Transplantation in Acute Myeloid Leukemia Patients. Biology of Blood and Marrow Transplantation, 2015, 21, 1425-1430.	2.0	12
53	GM-CSF secreting leukemia cell vaccination for MDS/AML after allogeneic HSCT: a randomized, double-blinded, phase 2 trial. Blood Advances, 2022, 6, 2183-2194.	5.2	12
54	Peritransplant Serum Albumin Decline Predicts Subsequent Severe Acute Graft-versus-Host Disease after Mucotoxic Myeloablative Conditioning. Biology of Blood and Marrow Transplantation, 2016, 22, 1137-1141.	2.0	11

#	Article	IF	Citations
55	Tweeting from the Bench: Twitter and the Physician-Scientist Benefits and Challenges. Current Hematologic Malignancy Reports, 2020, 15, 419-423.	2.3	11
56	The Predicted Indirectly Recognizable HLA Epitopes (PIRCHE) Score for HLA Class I Graft-versus-Host Disparity Is Associated with Increased Acute Graft-versus-Host Disease in Haploidentical Transplantation with Post-Transplantation Cyclophosphamide. Biology of Blood and Marrow Transplantation, 2020, 26, 123-131.	2.0	9
57	Combination of dociparstat sodium (DSTAT), a CXCL12/CXCR4 inhibitor, with azacitidine for the treatment of hypomethylating agent refractory AML and MDS. Leukemia Research, 2021, 110, 106713.	0.8	9
58	Human Cytokine-Induced Memory-like (CIML) NK Cells Are Active Against Myeloid Leukemia in Vitro and in Vivo. Blood, 2014, 124, 1117-1117.	1.4	9
59	Engineered Memory-like NK Cars Targeting a Neoepitope Derived from Intracellular NPM1c Exhibit Potent Activity and Specificity Against Acute Myeloid Leukemia. Blood, 2020, 136, 3-4.	1.4	8
60	Selinexor in Combination with Cladribine, Cytarabine and G-CSF for Relapsed or Refractory AML. Blood, 2017, 130, 816-816.	1.4	7
61	Invasive Yeast Infection after Haploidentical Donor Hematopoietic Cell Transplantation Associated with Cytokine Release Syndrome. Transplantation and Cellular Therapy, 2022, 28, 508.e1-508.e8.	1.2	6
62	Use of Post-Transplant Cyclophosphamide (PTCy) with Mycophenolate Mofetil and Tacrolimus in HLA Matched Allogeneic Hematopoietic Cell Transplant Is Safe and Associated with Acceptable Transplant Outcomes. Blood, 2015, 126, 1950-1950.	1.4	5
63	Do adults aged 70 years or older with acute myeloid leukemia benefit from allogeneic hematopoietic cell transplantation?. Leukemia, 2016, 30, 1797-1799.	7.2	4
64	Mir-15/16 Antagonizes Myb To Control Natural Killer Cell Differentiation and Maturation. Blood, 2013, 122, 17-17.	1.4	4
65	Human Cytokine-Induced Memory-like NK Cells Exhibit in Vivo Anti-Leukemia Activity in Xenografted NSG Mice and in Patients with Acute Myeloid Leukemia (AML). Blood, 2015, 126, 101-101.	1.4	4
66	HLA disparity is not inconsequential in peripheral blood T-replete haploidentical hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2016, 51, 1275-1278.	2.4	3
67	Single institution experience with G-CSF mobilized T-cell replete haploidentical hematopoietic cell transplantation. Bone Marrow Transplantation, 2017, 52, 769-771.	2.4	3
68	Prognostic value of prior consolidation in acute myeloid leukemia patients undergoing hematopoietic cell transplantation in minimal residual diseaseâ€negative first complete remission. American Journal of Hematology, 2018, 93, E381-E383.	4.1	3
69	Cutaneous graft-versus-host disease incidence is similar in haploidentical and matched unrelated hematopoietic transplant recipients: A retrospective cohort study. Journal of the American Academy of Dermatology, 2020, 83, 1654-1658.	1.2	3
70	A case of Epstein Barr virus-related post-transplant lymphoproliferative disorder after haploidentical allogeneic stem cell transplantation using post-transplantation cyclophosphamide. Haematologica, 2020, 105, e379-e381.	3.5	3
71	IL-15 Primes a Highly Potent Anti-Leukemia Response By CD56bright NK Cells. Blood, 2013, 122, 2283-2283.	1.4	3
72	Comparison of Peripheral Blood Stem Cells (PBSC) to Bone Marrow (BM) for T-Replete HLA-Haploidentical Donor Transplantation Using Post-Transplant Cyclophosphamide. Blood, 2016, 128, 683-683.	1.4	3

#	Article	IF	Citations
73	Acute myeloid leukemia presenting with extensive bone marrow necrosis, leukemia cutis and testicular involvement: successful treatment with allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplantation, 2016, 51, 454-455.	2.4	2
74	T-Replete Haploidentical Cell Transplantation Using Post-Transplant Cyclophosphamide for Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome: Effect of Transplant Conditioning Regimen Intensity on Outcomes. Blood, 2018, 132, 1015-1015.	1.4	2
75	A Phase I/II Trial of Intravenous Azacitidine for Acute Gvhd Prophylaxis in Patients Undergoing Matched Unrelated Stem Cell Transplantation: Phase I Results. Blood, 2015, 126, 1935-1935.	1.4	2
76	Autologous cellular therapy for myeloma: Giving exÂvivo expanded NK cells their due. Cell Reports Medicine, 2022, 3, 100537.	6.5	2
77	Graftâ€versusâ€host disease after liver transplantation: the effect of recipientâ€“donor age difference. Clinical Transplantation, 2016, 30, 335-336.	1.6	1
78	Use of Myeloablative or Reduced Intensity Conditioning with Haploidentical Hematopoietic Cell Transplantation for Acute Leukemia and MDS is Associated with Similar Outcomes. Biology of Blood and Marrow Transplantation, 2017, 23, S279.	2.0	1
79	Virescent tongue. Annals of Hematology, 2017, 96, 883-884.	1.8	1
80	Dynamic Changes in Clonal Clearance with Decitabine Therapy in AML and MDS Patients. Blood, 2015, 126, 689-689.	1.4	1
81	Cytokine Activation and CD16 Cross-Linking Leads to the Generation of Human Memory-Like NK Cells. Blood, 2012, 120, 3291-3291.	1.4	1
82	Cytokine Activation Induces CD25 Expression and a Signaling-Competent High-Affinity IL-2 Receptor On CD56dim Human NK Cells.. Blood, 2012, 120, 2159-2159.	1.4	1
83	Donor-to-Recipient Weight Ratio Is Independently Associated with CD34+ Yield in Healthy Donors Undergoing Peripheral Blood Stem Cell Collection for Allogeneic Transplantation. Blood, 2014, 124, 2456-2456.	1.4	1
84	KIR-HLA Interactions Lack Clinical Utility in Matched Unrelated Donor Transplantation for AML: An Analysis of the CIBMTR and DRST Registries. Blood, 2021, 138, 419-419.	1.4	1
85	Post-Transplant Vaccination with a Personalized Dendritic Cell/AML Fusion Cell Vaccine for Prevention of Relapse. Blood, 2021, 138, 2830-2830.	1.4	1
86	Early Reconstitution of CD6+ T Cells after Hematopoietic Cell Transplantation Identifies a Suitable Target for Acute Graft Versus Host Disease Treatment Using Anti-CD6 Monoclonal Antibody Itolizumab. Blood, 2020, 136, 10-11.	1.4	1
87	The Value of the Serum Aspergillus Galactomannan (GM) to Diagnose Invasive Aspergillosis (IA) and Invasive Fungal Infections (IFI) as Defined by European Organization of Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) in Recipients of Hematopoietic Stem Cell Transplants (HSCT).. Open Forum Infectious Diseases, 2016, 3, .	0.9	0
88	Allogeneic hematopoietic cell transplantation in morphologic leukemiaâ€free aplastic state. American Journal of Hematology, 2017, 92, E549-E552.	4.1	0
89	Primary or Secondary Prophylaxis with Voriconazole Compared with Posaconazole for Prevention of Invasive Fungal Infections After Hematopoietic Stem Cell Transplantation. Open Forum Infectious Diseases, 2017, 4, S75-S75.	0.9	0
90	Inducing Fat to Feed a Natural Killer of Malignancy. Molecular Therapy, 2019, 27, 898-899.	8.2	0

#	Article	IF	Citations
91	Plerixafor, G-CSF and Azacitidine For The Treatment Of MDS: Results Of a Phase I Trial. Blood, 2013, 122, 2816-2816.	1.4	0
92	Impact of Remission Status on Outcomes in AML Patients â‰¥ 60 Years of Age after Allogeneic Stem Cell Transplantation. Blood, 2014, 124, 1263-1263.	1.4	0
93	Remobilization with G-CSF Is Less Effective Than the Initial Mobilization in Healthy Donors Undergoing Peripheral Blood Stem Cell Collection for Allogeneic Transplantation. Blood, 2014, 124, 850-850.	1.4	0
94	Addition of Mycophenolate Mofetil to Methotrexate and Tacrolimus Does Not Improve Gvhd Outcomes in Reduced Intensity Allogeneic Hematopoietic Cell Transplantation. Blood, 2015, 126, 3144-3144.	1.4	0
95	T-Cell Replete Peripheral Blood Haploidentical Donor Transplant Is Frequently Associated with Cytokine Release Syndrome Which Responds to Anti-IL-6 Therapy. Blood, 2015, 126, 3106-3106.	1.4	0
96	Cytomegalovirus (CMV) disease in peripheral blood (PB) allogeneic hematopoietic cell transplant (HCT) with post-transplant cyclophosphamide (PT-Cy).. Journal of Clinical Oncology, 2016, 34, e18538-e18538.	1.6	0
97	Post-Transplant Outcomes in AML Patients â‰¥ 60 Years of Age Beyond CR1. Blood, 2016, 128, 4696-4696.	1.4	0
98	Haploidentical Transplant with Peripheral Blood Hematopoietic Cell Grafts in Older Adults with AML or MDS. Blood, 2016, 128, 4658-4658.	1.4	0
99	Haploidentical Hematopoietic Cell Transplantation Using G-CSF Mobilized T-Cell Replete Grafts for for Acute Leukemia and MDS. Blood, 2016, 128, 2278-2278.	1.4	0
100	Absolute Lymphocyte Count Recovery Predicts Post Transplant Outcomes in Peripheral Blood Haploidentical Transplantation. Blood, 2016, 128, 4698-4698.	1.4	0
101	HLA Class II Epitope Mismatch Influences Relapse and Engraftment in Peripheral Blood Haploidentical Hematopoietic Cell Transplantation. Blood, 2018, 132, 4634-4634.	1.4	0
102	ADAM17 and CD56low CD16low NK cells. Haematologica, 2015, 100, e331.	3.5	0
103	Defibrotide: Real World Experience for Management of Veno-Occlusive Disease/ Sinusoidal Obstructive Syndrome after Hematopoietic Stem Cell Transplantation. Blood, 2020, 136, 23-24.	1.4	0
104	Comparison of Outcomes after Haploidentical Relative and HLA Matched Unrelated Donor Transplantation with Post-Transplant Cyclophosphamide Containing Gvhd Prophylaxis Regimens. Blood, 2020, 136, 21-22.	1.4	0
105	Outcomes of IDH1- and IDH2-Mutated AML Patients Undergoing Allogeneic Hematopoietic Cell Transplantation. Blood, 2020, 136, 2-3.	1.4	0